[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100478296":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":10,"locations":29,"responsibleParty":48,"collaborators":10,"id":50,"slug":10,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Primary staging group I",null,"All patients will be treated according to standard practice. Patients in group I are patients that will be stratified for radical gastrectomy or endoscopic resection. Group I will undergo only a primary staging. All patients will take DECT and mpMRI examination within 1 week before surgery.",[13,14],"Diagnostic Test: DECT examination","Diagnostic Test: mpMRI examination",{"label":16,"type":10,"description":17,"interventionNames":18},"Restaging group II","Patients in group II are patients that will be stratified for neoadjuvant chemotherapy.\n\nGroup II will undergo a primary staging (DECT and mpMRI) and 1-2 times restaging (DECT and mpMRI).",[13,14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DIAGNOSTIC_TEST","DECT examination","DECT examinations will be performed using a 192-slice CT scanner (SOMATOM, Force, Siemens, Forchheim, Germany).",[9,16],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"mpMRI examination","The examinations were conducted on a 3-T MR scanner (MAGNETOM Skyra; Siemens Healthcare, Erlangen, Germany).",[9,16],[30],{"facility":31,"status":32,"city":33,"state":10,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Yu-Dong Zhang","RECRUITING","Nanjing","210029","China",{"type":37,"coordinates":38},"Point",[39,40],118.77778,32.06167,{"lat":40,"lon":39},[43],{"name":44,"role":45,"phone":46,"phoneExt":10,"email":47},"Yu-Dong Zhang, MD;PHD","CONTACT","15805151704","njmu_zyd@163.com",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100478296",false,"NCT05508126","Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer","Diagnostic Accuracy of Multi-parametric MRI and Dual-energy CT in Gastric Cancer: a Paired Validating Confirmatory Study","Inclusion Criteria:\n\n* Consecutive patients with preoperative pathologically confirmed GC by endoscopy and preoperative imaging data (DECT\u002FmpMRI) were included.\n* No contraindications for CT\u002FMRI examination\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients with a history of previous therapy.\n* Patients with recurrent gastric cancer\n* Patients with a history of severe allergy to contrast agents\n* Patients with imaging artefacts affect the evaluation","ALL","18 Years",{"count":59,"type":60},222,"ESTIMATED","OBSERVATIONAL","Accurate preoperative staging of gastric cancer is of major importance for guiding therapeutic decision-making, preventing both under- and over-treatment. The purpose of this study is to investigate the diagnostic performance of the Multi-parametric magnetic resonance imaging (mpMRI) and dual-energy computed tomography (DECT) in gastric cancer.",[64],"Gastric Cancer Stage",[66,67],"Computed Tomography","Magnetic Resonance Imaging","2024-10-10",{"date":70,"type":71},"2024-10-15","ACTUAL",{"date":73,"type":71},"2021-11-01",{"date":75,"type":60},"2026-12-31",{"name":5,"class":6},1]